Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch

Epidermal anti-Inflammatory properties of 5,11,14 20:3: Effects on mouse ear edema, PGE2 levels in cultured keratinocytes, and PPAR activation

Alvin Berger1,3 email, Irina Monnard1 email, Markus Baur1,4 email, Corinne Charbonnet1,5 email, Irina Safonova2 email and André Jomard2 email

Nestlé Research Center, Vers-Chez-les-Blanc, 1000 Lausanne 26, Switzerland

Galderma R&D, Route des Lucioles, BP 87, 06902 Sophia Antipolis, France

Current address: Cytochroma, Inc., Manager Lipidomics™, 330 Cochrane Drive, Markham, Ontario L3R 8E4, Canada

Current address: Boehringer Ingelheim Pharma KG, Biopharmaceutical Quality & Development, Head of Manufacturing Alliances, Birkendorfer Str. 65, 88397 Biberach / Riss, Germany

Current address: chemin de Vuichardaz 9, CH-1030 Bussigny-près-Lausanne, Switzerland

author email corresponding author email

Lipids in Health and Disease 2002, 1:5doi:10.1186/1476-511X-1-5

Published: 6 December 2002

Abstract

Background

5,11,14 20:3 is similar to 20:4n-6 but lacks the internal Δ8 double bond essential for prostaglandin and eicosanoid synthesis. When previously fed to laboratory animals as a gymnosperm seed oil component it has shown anti-inflammatory properties.

Results

Herein, topically applied Podocarpus nagi methyl esters (containing 26% 5,11,14 20:3) were incorporated into mouse ear phospholipids, reduced 20:4n-6, and reduced 20:4n-6- and TPA-induced mouse ear edema. Purified 5,11,14 20:3 was taken up by cultured human skin keratinocytes, reduced 20:4n-6, and reduced PGE2 levels dramatically. Purified 5,11,14 20:3 did not affect PPARα, PPARγ, or PPARδ transactivation.

Conclusions

Topical application of 5,11,14 20:3 to skin surfaces can thus reduce inflammatory processes, most likely by displacing 20:4n-6 from phospholipid pools and reducing downstream inflammatory products derived from 20:4n-6 such as PGE2 and leukotrienes. It could have potential use in treating clinical skin disorders resulting from overproduction of 20:4n-6-derived eicosanoid products.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.